keyword
MENU ▼
Read by QxMD icon Read
search

drug resistant AND tumor

keyword
https://www.readbyqxmd.com/read/30517668/sox2-in-cancer-stemness-tumor-malignancy-and-therapeutic-potentials
#1
Mahfuz Al Mamun, Kaiissar Mannoor, Jun Cao, Firdausi Qadri, Xiaoyuan Song
Cancer stem cells (CSCs), a minor subpopulation of tumor bulks with self-renewal and seeding capacity to generate new tumors, posit a significant challenge to develop effective and long-lasting anti-cancer therapies. The emergence of drug resistance appears upon failure of chemo-/radiation therapy to eradicate the CSCs, thereby leading to CSC-mediated clinical relapse. Accumulating evidence suggests that transcription factor SOX2, a master regulator of embryonic and induced pluripotent stem cells, drives cancer stemness, fuels tumor initiation, and contributes to tumor aggressiveness through major drug resistance mechanisms like epithelial-to-mesenchymal transition (EMT), ATP-binding cassette (ABC) drug transporters, anti-apoptotic and/or pro-survival signaling, lineage plasticity, and evasion of immune surveillance...
December 5, 2018: Journal of Molecular Cell Biology
https://www.readbyqxmd.com/read/30516854/cocktail-strategy-based-on-spatio-temporally-controlled-nano-device-improves-therapy-of-breast-cancer
#2
Tianqun Lang, Yiran Liu, Zhong Zheng, Wei Ran, Yihui Zhai, Qi Yin, Pengcheng Zhang, Yaping Li
Metastatic breast cancer may be resistant to chemo-immunotherapy due to the existence of cancer stem cells (CSC). And the control of particle size and drug release of a drug carrier for multidrug combination is a key issue influencing therapy effect. Here, a cocktail strategy is reported, in which chemotherapy against both bulk tumor cells and CSC and immune checkpoint blockade therapy are intergraded into one drug delivery system. The chemotherapeutic agent paclitaxel (PTX), the anti-CSC agent thioridazine (THZ), and the PD-1/PD-L1 inhibitor HY19991 (HY) are all incorporated into an enzyme/pH dual-sensitive nanoparticle with a micelle-liposome double-layer structure...
December 5, 2018: Advanced Materials
https://www.readbyqxmd.com/read/30516071/microrna-221-sensitizes-chronic-myeloid-leukemia-cells-to-imatinib-by-targeting-stat5
#3
Xiaoxiao Jiang, Yanhong Cheng, Chaojie Hu, Aimei Zhang, Yingli Ren, Xiucai Xu
MicroRNAs (miRNAs) are involved in various processes from the development to drug resistance of tumors, including chronic myeloid leukemia (CML). In this study, we examined the STAT5-related miRNA-expression profile in CML cell lines (K562 and imatinib-resistant K562/G) by quantitative real-time reverse-transcriptase polymerase chain reactions. MiR-221 expression was markedly decreased in K562/G cells and peripheral blood mononuclear cells from patients with treatment failure, when compared to imatinib-sensitive CML cells and patients with optimal responses respectively...
December 5, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30515806/challenges-facing-antiangiogenesis-therapy-the-significant-role-of-hypoxia-inducible-factor-and-met-in-development-of-resistance-to-anti-vascular-endothelial-growth-factor-targeted-therapies
#4
REVIEW
Ali Mahdi, Behrad Darvishi, Keivan Majidzadeh-A, Malihe Salehi, Leila Farahmand
It is now fully recognized that along with multiple physiological functions, angiogenesis is also involved in the fundamental process and pathobiology of several disorders including cancer. Recent studies have fully established the role of angiogenesis in cancer progression as well as invasion and metastasis. Consequently, many therapeutic agents such as monoclonal antibodies targeting angiogenesis pathway have been introduced in clinic with the hope for improving the outcomes of cancer therapy. Bevacizumab (Avastin®) was the first anti-vascular endothelial growth factor (VEGF) targeting monoclonal antibody developed with this purpose and soon received its accelerated US Food and Drug Administration (FDA) approval for treatment of patients with metastatic breast cancer in 2008...
December 4, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/30515264/targeting-the-invincible-barrier-for-drug-delivery-in-solid-cancers-interstitial-fluid-pressure
#5
Steven K Libutti, Lawrence Tamarkin, Naris Nilubol
Although a number of new systemic therapeutic options in patients with advanced solid cancers have emerged due to the improved knowledge of molecular dysregulation in cancers, the durable, long-term, objective responses infrequently occur. This editorial article highlights the major limitation of current systemic therapy due to an inefficient drug delivery. While several mechanisms contributing to cancer drug resistance have been described, the common key barrier among solid cancers is the unique tumor microenvironment that causes the high interstitial fluid pressure (IFP)...
November 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/30514390/activity-of-durvalumab-plus-olaparib-in-metastatic-castration-resistant-prostate-cancer-in-men-with-and-without-dna-damage-repair-mutations
#6
Fatima Karzai, David VanderWeele, Ravi A Madan, Helen Owens, Lisa M Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B Trepel, Maria J Merino, Ryan Dittamore, Jennifer Marté, Renee N Donahue, Jeffrey Schlom, Keith J Killian, Paul S Meltzer, Seth M Steinberg, James L Gulley, Jung-Min Lee, William L Dahut
BACKGROUND: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and locally advanced, unresectable stage 3 non-small cell lung cancer. Olaparib, a poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) in select patients with metastatic castration-resistant prostate cancer (mCRPC)...
December 4, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/30514230/egf-egfr-upregulates-and-cooperates-with-netrin-4-to-protect-glioblastoma-cells-from-dna-damage-induced-senescence
#7
Li Li, Yulun Huang, Yuge Gao, Tengfei Shi, Yunyun Xu, Huini Li, Marko Hyytiäinen, Jorma Keski-Oja, Qiuying Jiang, Yizhou Hu, Zhimin Du
BACKGROUND: Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of GBM cells to TMZ is affected by many factors. And, several clinic trials, including co-administration of TMZ with other drugs, have failed in successful treatment of GBM. We have previously reported that Netrin-4 (NTN4), a laminin-like axon guidance protein, plays a protective role in GBM cell senescence upon TMZ-triggered DNA damage...
December 4, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30513872/hgf-c-met-signaling-in-melanocytes-and-melanoma
#8
REVIEW
Malgorzata Czyz
Hepatocyte growth factor (HGF)/ mesenchymal-epithelial transition factor (c-MET) signaling is involved in complex cellular programs that are important for embryonic development and tissue regeneration, but its activity is also utilized by cancer cells during tumor progression. HGF and c-MET usually mediate heterotypic cell⁻cell interactions, such as epithelial⁻mesenchymal, including tumor⁻stroma interactions. In the skin, dermal fibroblasts are the main source of HGF. The presence of c-MET on keratinocytes is crucial for wound healing in the skin...
December 3, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30513833/gpcr-modulation-in-breast-cancer
#9
REVIEW
Rosamaria Lappano, Yves Jacquot, Marcello Maggiolini
Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration...
December 2, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30513765/current-landscape-and-the-potential-role-of-hypoxia-inducible-factors-and-selenium-in-clear-cell-renal-cell-carcinoma-treatment
#10
REVIEW
Rohan Garje, Josiah J An, Kevin Sanchez, Austin Greco, Jeffrey Stolwijk, Eric Devor, Youcef Rustum, Yousef Zakharia
In the last two decades, the discovery of various pathways involved in renal cell carcinoma (RCC) has led to the development of biologically-driven targeted therapies. Hypoxia-inducible factors (HIFs), angiogenic growth factors, von Hippel⁻Lindau ( VHL ) gene mutations, and oncogenic microRNAs (miRNAs) play essential roles in the pathogenesis and drug resistance of clear cell renal cell carcinoma. These insights have led to the development of vascular endothelial growth factor (VEGF) inhibitors, Mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapeutic agents, which have significantly improved the outcomes of patients with advanced RCC...
December 1, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30513596/propranolol-promotes-glucose-dependence-and-synergizes-with-dichloroacetate-for-anti-cancer-activity-in-hnscc
#11
Christopher T Lucido, W Keith Miskimins, Paola D Vermeer
Tumor cell metabolism differs from that of normal cells, conferring tumors with metabolic advantages but affording opportunities for therapeutic intervention. Accordingly, metabolism-targeting therapies have shown promise. However, drugs targeting singular metabolic pathways display limited efficacy, in part due to the tumor's ability to compensate by using other metabolic pathways to meet energy and growth demands. Thus, it is critical to identify novel combinations of metabolism-targeting drugs to improve therapeutic efficacy in the face of compensatory cellular response mechanisms...
November 30, 2018: Cancers
https://www.readbyqxmd.com/read/30513337/styryl-cinnamate-hybrid-inhibits-glioma-by-alleviating-translation-bioenergetics-and-other-key-cellular-responses-leading-to-apoptosis
#12
Kiran Rawat, Amit Shard, Manali Jadhav, Mayuri Gandhi, Prince Anand, Rituraj Purohit, Yogendra Padwad, Arun K Sinha
Gliomas are lethal and aggressive form of brain tumors with resistance to conventional radiation and cytotoxic chemotherapies; inviting continuous efforts for drug discovery and drug delivery. Interestingly, small molecule hybrids are one such pharmacophore that continues to capture interest owing to their pluripotent medicinal effects. Accordingly, we earlier reported synthesis of potent Styryl-cinnamate hybrids (analogues of Salvianolic acid F) along with its plausible mode of action (MOA). We explored iTRAQ-LC/MS-MS technique to deduce differentially expressed landscape of native & phospho-proteins in treated glioma cells...
December 1, 2018: Experimental Cell Research
https://www.readbyqxmd.com/read/30511935/dynamic-expression-of-11-mirnas-in-83-consecutive-primary-and-corresponding-recurrent-glioblastoma-correlation-to-treatment-time-to-recurrence-overall-survival-and-mgmt-methylation-status
#13
Bostjan Matos, Emanuela Bostjancic, Alenka Matjasic, Mara Popovic, Damjan Glavac
Background Glioblastoma (GBM) is the most common and the most malignant glioma subtype. Among numerous genetic alterations, miRNAs contribute to pathogenesis of GBM and it is suggested that also to GBM recurrence and resistance to therapy. Based on publications, we have selected 11 miRNAs and analyzed their expression in GBM. We hypothesized that selected miRNAs are differentially expressed and involved in primary as well as in recurrent GBM, that show significant expressional differences when different treatment options are in question, and that are related to certain patients and tumor characteristics...
November 26, 2018: Radiology and Oncology
https://www.readbyqxmd.com/read/30510640/incidence-and-risk-factors-for-potentially-suboptimal-serum-concentrations-of-vancomycin-during-cardiac-surgery
#14
Paolo Cotogni, Cristina Barbero, Mauro Rinaldi
AIM: To investigate the incidence and risk factors for vancomycin concentrations less than 10 mg/L during cardiac surgery. METHODS: In this prospective study, patients undergoing cardiac surgery received a single dose of 1000 mg of vancomycin. Multiple arterial samples were drawn during surgery. Exclusion criteria were hepatic dysfunction; renal dysfunction; ongoing infectious diseases; solid or hematologic tumors; severe insulin-dependent diabetes; body mass index of < 17 or > 40 kg/m2 ; pregnancy or lactation; antibiotic, corticosteroid, or other immunosuppressive therapy; vancomycin or nonsteroidal anti-inflammatory drug therapy in the previous 2 wk; chemotherapy or radiation therapy in the previous 6 mo; allergy to vancomycin or cefazolin; drug abuse; cardiac surgery in the previous 6 mo; previous or scheduled organ transplantation; preoperative stay in the intensive care unit for more than 24 h; emergency procedure or lack of adequate preparation for surgery; and participation in another trial...
November 26, 2018: World Journal of Cardiology
https://www.readbyqxmd.com/read/30510209/complex-role-of-mir-130a-3p-and-mir-148a-3p-balance-on-drug-resistance-and-tumor-biology-in-esophageal-squamous-cell-carcinoma
#15
A K Eichelmann, C Matuszcak, K Lindner, J Haier, D J Hussey, R Hummel
miRNAs play a crucial role in cancer development and progression. However, results on the impact of miRNAs on drug sensitivity and tumor biology vary, and most studies to date focussed on either increasing or decreasing miRNA expression levels. Therefore, the current study investigated the role of different expression levels of miR-130a-3p and miR-148a-3p on drug resistance and tumor biology in four esophageal squamous cell carcinoma cell lines. Interestingly, up- and downregulation of both miRNAs significantly increased sensitivity towards chemotherapy...
December 3, 2018: Scientific Reports
https://www.readbyqxmd.com/read/30510142/xpo1-inhibitor-selinexor-overcomes-intrinsic-ibrutinib-resistance-in-mantle-cell-lymphoma-via-nuclear-retention-of-i%C3%AE%C2%BAb
#16
Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, Y Lynn Wang
Inhibition of B-cell receptor (BCR) signaling through the BTK inhibitor, ibrutinib, has generated a remarkable response in mantle cell lymphoma (MCL). However, approximately one third of patients do not respond well to the drug, and disease relapse on ibrutinib is nearly universal. Alternative therapeutic strategies aimed to prevent and overcome ibrutinib resistance are needed. We compared and contrasted the effects of selinexor, a selective inhibitor of nuclear export, with ibrutinib in six MCL cell lines that display differential intrinsic sensitivity to ibrutinib...
December 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/30509983/mycoplasma-promotes-malignant-transformation-in-vivo-and-its-dnak-a-bacterial-chaperon-protein-has-broad-oncogenic-properties
#17
Davide Zella, Sabrina Curreli, Francesca Benedetti, Selvi Krishnan, Fiorenza Cocchi, Olga S Latinovic, Frank Denaro, Fabio Romerio, Muhammad Djavani, Man E Charurat, Joseph L Bryant, Hervé Tettelin, Robert C Gallo
We isolated a strain of human mycoplasma that promotes lymphomagenesis in SCID mice, pointing to a p53-dependent mechanism similar to lymphomagenesis in uninfected p53-/- SCID mice. Additionally, mycoplasma infection in vitro reduces p53 activity. Immunoprecipitation of p53 in mycoplasma-infected cells identified several mycoplasma proteins, including DnaK, a member of the Hsp70 chaperon family. We focused on DnaK because of its ability to interact with proteins. We demonstrate that mycoplasma DnaK interacts with and reduces the activities of human proteins involved in critical cellular pathways, including DNA-PK and PARP1, which are required for efficient DNA repair, and binds to USP10 (a key p53 regulator), impairing p53-dependent anticancer functions...
December 3, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/30509077/neoadjuvant-therapy-theoretical-biological-and-medical-consideration
#18
Evgeny N Imyanitov, Grigoriy A Yanus
Neoadjuvant therapy (NAT) is widely utilized in the routine management of cancer patients and various clinical trials for the treatment of breast, ovarian, rectal, esophageal, head and neck, lung, prostate and many other cancer types. There is a number of potential benefits of applying systemic treatment before the operation. NAT may significantly reduce the tumor burden thus allowing less traumatic surgery. NAT is often considered as personalized in vivo drug sensitivity test, as it allows rapid evaluation of tumor response to a given therapy and consequent adjustment of further treatment planning...
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30508668/discovery-of-a-highly-selective-flt3-inhibitor-with-specific-proliferation-inhibition-against-aml-cells-harboring-flt3-itd-mutation
#19
Hao Heng, Yanle Zhi, Haoliang Yuan, Zhijie Wang, Hongmei Li, Shuxian Wang, Jieyi Tian, Haichun Liu, Yadong Chen, Tao Lu, Ting Ran, Shuai Lu
FLT3 is often over-expressed in AML, and FLT3 mutants, especially FLT-ITD, are closely related to the poor prognosis in AML patients. Thus, FLT3 has become an attractive target for AML therapy. A series of FLT3 inhibitors have been evaluated in various clinical trials, one of which was approved for AML. However, current FLT3 inhibitors still faced the challenges of kinase selectivity and drug resistance due to concurrent FLT3-ITD-TKD mutations. In this work, a new FLT3 inhibitor (compound 1) with simple structure was discovered through virtually screening an in-house molecule database which contains numerous compounds with kinase-inhibition activity...
November 27, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/30508483/discovery-of-non-quinone-substrates-for-nad-p-h-quinone-oxidoreductase-1-nqo1-as-effective-intracellular-ros-generators-for-the-treatment-of-drug-resistant-non-small-cell-lung-cancer
#20
Xingsen Wu, Xiang Li, Zhihong Li, Yancheng Yu, Qi-Dong You, Xiaojin Zhang
The elevation of oxidative stress preferentially in cancer cells by efficient NQO1 substrates which promote ROS generation through redox cycling has emerged as an effective strategy for cancer therapy, even for treating drug-resistant cancers. Here, we described the identification and structural optimization studies of the hit compound 1, a new chemotype of non-quinone substrate for NQO1 as an efficient ROS generator. Further structure-activity relationship studies resulted in the most active compound 20k, a tricyclic 2,3-dicyano indenopyrazinone, which selectively inhibited the proliferation of NQO1-overexpressing A549 and A549/Taxol cancer cells...
December 3, 2018: Journal of Medicinal Chemistry
keyword
keyword
171001
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"